A Platform Study of RAS(ON) Inhibitors in Patients with Gastrointestinal Solid Tumors

Contact:

212-342-5162

NCT Number:

NCT06445062

Protocol:

AAAV2056

Study Status:

Active/Enrolling

Population:

Adult

Phase:

I/II

The purpose of this study is to test the safety of an experimental drug called RMC-6236 in combination with several chemotherapy medicines in patients with gastrointestinal cancers. The study will test the safety of RMC-6236 at different doses in combination with a fixed, standard dose of combination anti-cancer therapy, and how your body processes this combination. RMC-6236 is an investigational (experimental) drug, which means that it has not been approved by the United States (US) Food and Drug Administration (FDA).

Are you Eligible? (Inclusion Criteria)

  • Must be 18 years old or older - Must be able to take oral medications - Must be willing to keep daily record in the provided diary

Specialty Area(s)

Colon and Rectal Cancer, Pancreatic Cancer, Immunotherapy

Principal Investigator

Gulam A. Manji, MD

Profile Headshot
  • Director of Gastrointestinal Oncology
  • Director of Pancreas Translational Research
  • Co-Director of The Pancreas Center

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
Open location in Google Maps